| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligodendroglia | 24 | 2015 | 124 | 3.160 |
Why?
|
| Myasthenia Gravis | 9 | 2022 | 83 | 2.390 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 6 | 2016 | 10 | 2.110 |
Why?
|
| Neuritis, Autoimmune, Experimental | 5 | 2015 | 7 | 1.910 |
Why?
|
| Receptors, Lysosphingolipid | 7 | 2015 | 37 | 1.720 |
Why?
|
| Polyneuropathies | 5 | 2023 | 27 | 1.600 |
Why?
|
| Sphingosine | 10 | 2011 | 74 | 1.200 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 2334 | 1.180 |
Why?
|
| Myelin Sheath | 8 | 2017 | 85 | 1.110 |
Why?
|
| B-Lymphocytes, Regulatory | 2 | 2016 | 8 | 1.090 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 2 | 2015 | 4 | 1.030 |
Why?
|
| Demyelinating Diseases | 7 | 2011 | 67 | 0.970 |
Why?
|
| Interleukin-10 | 4 | 2016 | 151 | 0.860 |
Why?
|
| Potassium Channels | 8 | 2004 | 343 | 0.830 |
Why?
|
| Propylene Glycols | 6 | 2011 | 30 | 0.780 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 178 | 0.760 |
Why?
|
| Signal Transduction | 9 | 2019 | 3361 | 0.740 |
Why?
|
| B7-2 Antigen | 4 | 2016 | 40 | 0.740 |
Why?
|
| Cells, Cultured | 22 | 2020 | 2873 | 0.730 |
Why?
|
| Receptors, Cholinergic | 4 | 2016 | 77 | 0.730 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 126 | 0.710 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 124 | 0.710 |
Why?
|
| Animals | 51 | 2017 | 27155 | 0.680 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 736 | 0.680 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2001 | 699 | 0.680 |
Why?
|
| CD5 Antigens | 2 | 2015 | 14 | 0.660 |
Why?
|
| Antigens, CD1d | 2 | 2015 | 32 | 0.650 |
Why?
|
| Spleen | 3 | 2016 | 431 | 0.650 |
Why?
|
| Mice, Inbred NOD | 7 | 2016 | 194 | 0.630 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2016 | 301 | 0.610 |
Why?
|
| Cytokines | 4 | 2016 | 801 | 0.590 |
Why?
|
| Neuroglia | 6 | 2011 | 105 | 0.580 |
Why?
|
| Schwann Cells | 4 | 2016 | 34 | 0.580 |
Why?
|
| Muscle, Skeletal | 8 | 2024 | 464 | 0.580 |
Why?
|
| Mice, Knockout | 9 | 2015 | 1986 | 0.570 |
Why?
|
| Stem Cells | 5 | 2010 | 369 | 0.570 |
Why?
|
| Lysophospholipids | 3 | 2011 | 66 | 0.550 |
Why?
|
| Mice | 23 | 2017 | 11690 | 0.540 |
Why?
|
| Electromyography | 5 | 2024 | 192 | 0.530 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2015 | 40 | 0.520 |
Why?
|
| Neurogenesis | 1 | 2015 | 75 | 0.500 |
Why?
|
| Rats | 17 | 2014 | 4027 | 0.500 |
Why?
|
| Axons | 5 | 2017 | 177 | 0.500 |
Why?
|
| Immunosuppressive Agents | 6 | 2011 | 994 | 0.490 |
Why?
|
| Dendritic Cells | 2 | 2015 | 436 | 0.490 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 112 | 0.480 |
Why?
|
| Thiophenes | 2 | 2015 | 43 | 0.470 |
Why?
|
| Oxadiazoles | 2 | 2015 | 38 | 0.470 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 41 | 0.470 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2024 | 187 | 0.460 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2009 | 87 | 0.450 |
Why?
|
| Myelin P0 Protein | 2 | 2014 | 3 | 0.450 |
Why?
|
| Cuprizone | 2 | 2011 | 3 | 0.450 |
Why?
|
| Cell Survival | 11 | 2015 | 980 | 0.440 |
Why?
|
| Autoimmunity | 2 | 2016 | 167 | 0.430 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 27 | 0.410 |
Why?
|
| Lymph Nodes | 1 | 2016 | 546 | 0.410 |
Why?
|
| Potassium | 7 | 1995 | 253 | 0.410 |
Why?
|
| Myelin Basic Protein | 5 | 2015 | 50 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 9 | 2017 | 3196 | 0.390 |
Why?
|
| Neurobiology | 1 | 2011 | 10 | 0.390 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1640 | 0.380 |
Why?
|
| Terbutaline | 2 | 2008 | 16 | 0.360 |
Why?
|
| Female | 32 | 2024 | 45647 | 0.350 |
Why?
|
| Cardiomyopathies | 2 | 2022 | 260 | 0.340 |
Why?
|
| Sciatic Nerve | 5 | 2017 | 34 | 0.340 |
Why?
|
| Fingolimod Hydrochloride | 6 | 2011 | 30 | 0.340 |
Why?
|
| Nerve Regeneration | 3 | 2010 | 34 | 0.340 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2008 | 3 | 0.330 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 72 | 0.320 |
Why?
|
| Diabetic Neuropathies | 3 | 2023 | 41 | 0.320 |
Why?
|
| Calcium | 5 | 1998 | 1170 | 0.300 |
Why?
|
| Down-Regulation | 4 | 2014 | 518 | 0.290 |
Why?
|
| Up-Regulation | 3 | 2007 | 729 | 0.290 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2007 | 68 | 0.290 |
Why?
|
| Neural Conduction | 8 | 2023 | 71 | 0.290 |
Why?
|
| Immunologic Factors | 3 | 2020 | 170 | 0.290 |
Why?
|
| Corpus Callosum | 3 | 2015 | 59 | 0.280 |
Why?
|
| Arachidonic Acid | 2 | 1997 | 63 | 0.280 |
Why?
|
| T-Lymphocytes | 2 | 2011 | 1216 | 0.280 |
Why?
|
| Immune Tolerance | 3 | 2015 | 338 | 0.270 |
Why?
|
| Central Nervous System Diseases | 1 | 2006 | 52 | 0.270 |
Why?
|
| Ganglia, Sympathetic | 3 | 1995 | 8 | 0.260 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 63 | 0.260 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 169 | 0.260 |
Why?
|
| Thymectomy | 2 | 2022 | 31 | 0.260 |
Why?
|
| Cell Communication | 2 | 2005 | 197 | 0.260 |
Why?
|
| Ceramides | 3 | 2001 | 35 | 0.260 |
Why?
|
| Flow Cytometry | 3 | 2016 | 691 | 0.250 |
Why?
|
| Humans | 41 | 2024 | 88403 | 0.250 |
Why?
|
| Aged | 16 | 2024 | 18887 | 0.240 |
Why?
|
| Neurons | 5 | 2011 | 1565 | 0.240 |
Why?
|
| Isometric Contraction | 1 | 2024 | 42 | 0.240 |
Why?
|
| Male | 24 | 2024 | 41917 | 0.240 |
Why?
|
| Th1 Cells | 2 | 2016 | 165 | 0.230 |
Why?
|
| Cyclic AMP | 4 | 2001 | 274 | 0.230 |
Why?
|
| Animals, Newborn | 7 | 2017 | 520 | 0.230 |
Why?
|
| Guillain-Barre Syndrome | 2 | 2019 | 16 | 0.220 |
Why?
|
| Middle Aged | 17 | 2024 | 25625 | 0.220 |
Why?
|
| src-Family Kinases | 1 | 2003 | 76 | 0.220 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2003 | 80 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 64 | 0.210 |
Why?
|
| Young Adult | 5 | 2024 | 6188 | 0.210 |
Why?
|
| Steroids | 2 | 2022 | 175 | 0.210 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2001 | 226 | 0.210 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2003 | 122 | 0.200 |
Why?
|
| Cell Differentiation | 5 | 2016 | 1513 | 0.200 |
Why?
|
| Suramin | 3 | 2008 | 27 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2019 | 656 | 0.190 |
Why?
|
| Interferon-gamma | 2 | 2001 | 450 | 0.190 |
Why?
|
| Sympathetic Nervous System | 3 | 1992 | 94 | 0.190 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2023 | 240 | 0.190 |
Why?
|
| Potassium Channel Blockers | 2 | 2004 | 64 | 0.190 |
Why?
|
| Apoptosis | 4 | 2008 | 1715 | 0.190 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 7 | 0.190 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2000 | 50 | 0.180 |
Why?
|
| Lymphotoxin-alpha | 1 | 2000 | 44 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 1401 | 0.180 |
Why?
|
| Biomarkers | 2 | 2024 | 1754 | 0.180 |
Why?
|
| Adult | 13 | 2024 | 26278 | 0.180 |
Why?
|
| Neuromuscular Junction | 3 | 2010 | 81 | 0.180 |
Why?
|
| Thymoma | 1 | 2020 | 30 | 0.180 |
Why?
|
| Calcium Signaling | 1 | 2001 | 138 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 53 | 0.180 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 43 | 0.180 |
Why?
|
| Nitric Oxide | 1 | 2001 | 279 | 0.170 |
Why?
|
| Sphingolipids | 1 | 1999 | 20 | 0.170 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 86 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 205 | 0.170 |
Why?
|
| Phosphorylation | 4 | 2015 | 1128 | 0.170 |
Why?
|
| Facial Paralysis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Mutation | 8 | 2022 | 4092 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1998 | 48 | 0.160 |
Why?
|
| Facial Nerve | 1 | 2019 | 33 | 0.160 |
Why?
|
| Membrane Potentials | 7 | 1998 | 436 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2011 | 797 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 289 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 3 | 2007 | 511 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 145 | 0.160 |
Why?
|
| Electrophysiology | 4 | 2017 | 402 | 0.150 |
Why?
|
| Pyridostigmine Bromide | 3 | 2020 | 11 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2023 | 562 | 0.150 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 1998 | 121 | 0.150 |
Why?
|
| ras Proteins | 1 | 1998 | 130 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 399 | 0.150 |
Why?
|
| Motor Neurons | 2 | 2024 | 171 | 0.150 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 3 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 122 | 0.150 |
Why?
|
| Motor Neuron Disease | 1 | 1997 | 21 | 0.140 |
Why?
|
| Head Movements | 1 | 2017 | 39 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2010 | 162 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 201 | 0.140 |
Why?
|
| Vital Capacity | 1 | 2016 | 68 | 0.140 |
Why?
|
| Peripheral Nervous System | 1 | 2016 | 21 | 0.140 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 102 | 0.140 |
Why?
|
| Th1-Th2 Balance | 1 | 2016 | 4 | 0.140 |
Why?
|
| Gastrostomy | 1 | 2016 | 69 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2016 | 40 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2015 | 16 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 97 | 0.130 |
Why?
|
| Electric Conductivity | 5 | 1995 | 144 | 0.130 |
Why?
|
| Adolescent | 2 | 2020 | 9134 | 0.130 |
Why?
|
| Colforsin | 2 | 2001 | 74 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2020 | 45 | 0.130 |
Why?
|
| H-Reflex | 2 | 2007 | 8 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 393 | 0.130 |
Why?
|
| Melanoma | 1 | 2019 | 462 | 0.120 |
Why?
|
| Mitogens | 2 | 2007 | 63 | 0.120 |
Why?
|
| Protein Kinase C | 3 | 2005 | 268 | 0.120 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 131 | 0.120 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 1994 | 2 | 0.120 |
Why?
|
| Astrocytes | 3 | 2010 | 141 | 0.120 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1994 | 25 | 0.120 |
Why?
|
| Myelin Proteins | 1 | 2014 | 13 | 0.120 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 22 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6706 | 0.120 |
Why?
|
| Guinea Pigs | 1 | 2014 | 172 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1296 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 163 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2015 | 460 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2014 | 81 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2005 | 68 | 0.110 |
Why?
|
| Cell Line, Transformed | 2 | 2005 | 155 | 0.110 |
Why?
|
| Nicotine | 1 | 1995 | 199 | 0.110 |
Why?
|
| Gene Expression | 2 | 2016 | 1310 | 0.110 |
Why?
|
| Cell Lineage | 2 | 2007 | 291 | 0.110 |
Why?
|
| Arachidonic Acids | 1 | 1993 | 40 | 0.110 |
Why?
|
| Mice, Transgenic | 4 | 2010 | 1568 | 0.110 |
Why?
|
| omega-Conotoxins | 1 | 1992 | 2 | 0.110 |
Why?
|
| Rabbits | 1 | 2014 | 640 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2015 | 455 | 0.110 |
Why?
|
| Postpoliomyelitis Syndrome | 1 | 1992 | 6 | 0.110 |
Why?
|
| Prealbumin | 2 | 2022 | 34 | 0.110 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 1992 | 24 | 0.110 |
Why?
|
| Microscopy, Electron | 2 | 2011 | 506 | 0.100 |
Why?
|
| Tubocurarine | 1 | 1991 | 1 | 0.100 |
Why?
|
| Isoflurophate | 1 | 1991 | 3 | 0.100 |
Why?
|
| Edrophonium | 1 | 1991 | 3 | 0.100 |
Why?
|
| Motor Endplate | 1 | 1991 | 31 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 891 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 466 | 0.100 |
Why?
|
| Catecholamines | 1 | 1992 | 92 | 0.100 |
Why?
|
| Sheep | 5 | 1994 | 250 | 0.100 |
Why?
|
| Hypoxia | 1 | 2017 | 650 | 0.100 |
Why?
|
| Galvanic Skin Response | 2 | 1989 | 12 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2017 | 135 | 0.100 |
Why?
|
| Ganglia, Spinal | 3 | 2007 | 74 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1788 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 111 | 0.100 |
Why?
|
| Rats, Inbred Strains | 3 | 1995 | 312 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 81 | 0.090 |
Why?
|
| Isoproterenol | 1 | 1990 | 62 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 73 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2022 | 2280 | 0.090 |
Why?
|
| Arm | 2 | 2024 | 96 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 1944 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 94 | 0.090 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1990 | 73 | 0.090 |
Why?
|
| Agrin | 2 | 2010 | 6 | 0.090 |
Why?
|
| Central Nervous System | 1 | 2011 | 152 | 0.090 |
Why?
|
| Myasthenic Syndromes, Congenital | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cell Line | 3 | 2010 | 2498 | 0.090 |
Why?
|
| Lymphoma | 1 | 2011 | 264 | 0.090 |
Why?
|
| Paraplegia | 1 | 2009 | 17 | 0.090 |
Why?
|
| Blood-Nerve Barrier | 1 | 2009 | 2 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 129 | 0.090 |
Why?
|
| Prednisone | 3 | 2020 | 258 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2010 | 134 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 539 | 0.080 |
Why?
|
| Phorbol Esters | 1 | 1988 | 22 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 645 | 0.080 |
Why?
|
| 4-Aminopyridine | 2 | 2004 | 32 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 166 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2011 | 469 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 1999 | 1019 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 192 | 0.080 |
Why?
|
| Placebos | 1 | 2008 | 213 | 0.080 |
Why?
|
| Cerebellum | 1 | 2010 | 249 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2008 | 261 | 0.080 |
Why?
|
| Somatosensory Disorders | 1 | 2007 | 3 | 0.080 |
Why?
|
| Pain | 1 | 2011 | 399 | 0.080 |
Why?
|
| Organophosphates | 1 | 2007 | 6 | 0.080 |
Why?
|
| Dyneins | 1 | 2007 | 14 | 0.080 |
Why?
|
| Culture Media, Serum-Free | 1 | 2007 | 21 | 0.080 |
Why?
|
| Cell Surface Extensions | 1 | 2008 | 11 | 0.080 |
Why?
|
| Encephalitis | 1 | 2008 | 104 | 0.080 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 181 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 390 | 0.080 |
Why?
|
| Brain Stem | 1 | 2008 | 167 | 0.070 |
Why?
|
| Mitosis | 1 | 2007 | 152 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 927 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2000 | 1231 | 0.070 |
Why?
|
| Depression | 1 | 2011 | 495 | 0.070 |
Why?
|
| Ranvier's Nodes | 2 | 2003 | 4 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 274 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 3028 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 798 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2006 | 100 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 1997 | 1763 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 2 | 1998 | 396 | 0.070 |
Why?
|
| Antibodies | 1 | 1988 | 354 | 0.070 |
Why?
|
| Muscle Hypertonia | 1 | 2005 | 17 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2005 | 33 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 121 | 0.070 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2005 | 2 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2008 | 865 | 0.070 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2005 | 7 | 0.070 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 15 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2005 | 22 | 0.070 |
Why?
|
| Remission Induction | 3 | 2019 | 734 | 0.060 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2005 | 13 | 0.060 |
Why?
|
| Membrane Microdomains | 1 | 2005 | 54 | 0.060 |
Why?
|
| Cell Membrane | 3 | 2003 | 667 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2024 | 4265 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2005 | 79 | 0.060 |
Why?
|
| Muscular Dystrophies | 1 | 2005 | 55 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 109 | 0.060 |
Why?
|
| Gliosis | 1 | 2004 | 35 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 2061 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 727 | 0.060 |
Why?
|
| Transgenes | 1 | 2005 | 182 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1712 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2004 | 69 | 0.060 |
Why?
|
| Weight-Bearing | 1 | 2024 | 67 | 0.060 |
Why?
|
| Skin | 1 | 1987 | 577 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 155 | 0.060 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2003 | 29 | 0.060 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2003 | 31 | 0.060 |
Why?
|
| Homeostasis | 1 | 2005 | 407 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 956 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1841 | 0.060 |
Why?
|
| Norepinephrine | 2 | 1995 | 169 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 171 | 0.060 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 2003 | 13 | 0.060 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2003 | 12 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2003 | 113 | 0.060 |
Why?
|
| Nervous System | 1 | 2003 | 87 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 9 | 0.050 |
Why?
|
| Nifedipine | 2 | 1993 | 25 | 0.050 |
Why?
|
| Hindlimb | 2 | 2016 | 92 | 0.050 |
Why?
|
| Technetium | 1 | 2022 | 29 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Spinal Nerve Roots | 1 | 2002 | 17 | 0.050 |
Why?
|
| Neurofibromatoses | 1 | 2002 | 9 | 0.050 |
Why?
|
| Xenopus | 1 | 2003 | 126 | 0.050 |
Why?
|
| Recurrence | 2 | 2019 | 1168 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 226 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 1995 | 425 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2005 | 679 | 0.050 |
Why?
|
| Nervous System Autoimmune Disease, Experimental | 1 | 2001 | 1 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 8859 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 661 | 0.050 |
Why?
|
| Neuroimmunomodulation | 1 | 2001 | 11 | 0.050 |
Why?
|
| Cell Count | 2 | 2007 | 197 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2001 | 45 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2001 | 87 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 126 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 25 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2000 | 36 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 43 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 67 | 0.050 |
Why?
|
| Jews | 1 | 2020 | 42 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 122 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2000 | 84 | 0.050 |
Why?
|
| Cyclins | 1 | 2000 | 83 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 19 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 80 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2001 | 267 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2000 | 81 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2020 | 134 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 102 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1999 | 77 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 464 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2020 | 170 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2000 | 183 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 125 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 372 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 431 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 115 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2019 | 61 | 0.040 |
Why?
|
| Aging | 2 | 2001 | 708 | 0.040 |
Why?
|
| Reaction Time | 2 | 1992 | 310 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 158 | 0.040 |
Why?
|
| Insulin | 1 | 2023 | 1153 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 166 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 1999 | 698 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2017 | 2832 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 358 | 0.040 |
Why?
|
| Transfection | 1 | 1999 | 912 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 268 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2005 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 8139 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2016 | 15 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1998 | 307 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 995 | 0.040 |
Why?
|
| Cytoskeleton | 2 | 2008 | 194 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2017 | 60 | 0.040 |
Why?
|
| Kinetics | 2 | 1990 | 1528 | 0.040 |
Why?
|
| Integrases | 1 | 2016 | 60 | 0.030 |
Why?
|
| Models, Neurological | 1 | 1999 | 407 | 0.030 |
Why?
|
| Pseudopodia | 1 | 2016 | 36 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 282 | 0.030 |
Why?
|
| Carbachol | 1 | 1995 | 36 | 0.030 |
Why?
|
| Rats, Inbred Lew | 2 | 1994 | 192 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 417 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 97 | 0.030 |
Why?
|
| Dimethylphenylpiperazinium Iodide | 1 | 1995 | 8 | 0.030 |
Why?
|
| Histamine | 1 | 1995 | 126 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3432 | 0.030 |
Why?
|
| Neurites | 1 | 1995 | 36 | 0.030 |
Why?
|
| Cytological Techniques | 1 | 1995 | 30 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1995 | 154 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1095 | 0.030 |
Why?
|
| 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase | 1 | 1994 | 3 | 0.030 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 1994 | 10 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1308 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1995 | 314 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1994 | 51 | 0.030 |
Why?
|
| Linoleic Acids | 1 | 1993 | 3 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 1993 | 5 | 0.030 |
Why?
|
| Fura-2 | 1 | 1993 | 22 | 0.030 |
Why?
|
| Cobalt | 1 | 1993 | 30 | 0.030 |
Why?
|
| Prostaglandins | 1 | 1993 | 42 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 1993 | 36 | 0.030 |
Why?
|
| Indomethacin | 1 | 1993 | 59 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1044 | 0.030 |
Why?
|
| Manganese | 1 | 1993 | 54 | 0.030 |
Why?
|
| Fluorescence | 1 | 1993 | 102 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1542 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 1995 | 316 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 759 | 0.030 |
Why?
|
| Mollusk Venoms | 1 | 1992 | 2 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 1993 | 120 | 0.030 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1992 | 13 | 0.030 |
Why?
|
| Barium | 1 | 1992 | 31 | 0.030 |
Why?
|
| Peroneal Nerve | 1 | 1992 | 9 | 0.030 |
Why?
|
| Ion Channel Gating | 1 | 1995 | 325 | 0.030 |
Why?
|
| Electrodiagnosis | 1 | 1992 | 7 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1992 | 44 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1857 | 0.030 |
Why?
|
| 2-Chloroadenosine | 1 | 2011 | 5 | 0.030 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2011 | 9 | 0.030 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 10 | 0.030 |
Why?
|
| Deoxyadenosines | 1 | 2011 | 23 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1991 | 83 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1993 | 182 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1991 | 90 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 77 | 0.020 |
Why?
|
| Muscles | 1 | 1991 | 193 | 0.020 |
Why?
|
| Time Factors | 2 | 2008 | 5301 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 119 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 73 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 295 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 300 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2011 | 239 | 0.020 |
Why?
|
| Lysophosphatidylcholines | 1 | 2010 | 18 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 1991 | 225 | 0.020 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2010 | 18 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 289 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 52 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 1991 | 427 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2010 | 81 | 0.020 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2009 | 18 | 0.020 |
Why?
|
| Phosphatidate Phosphatase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Microglia | 1 | 2010 | 106 | 0.020 |
Why?
|
| Psychosine | 1 | 1989 | 3 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 331 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 1988 | 41 | 0.020 |
Why?
|
| Tetraethylammonium Compounds | 1 | 1988 | 14 | 0.020 |
Why?
|
| Serum | 1 | 2008 | 25 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2008 | 10 | 0.020 |
Why?
|
| Cesium | 1 | 1988 | 25 | 0.020 |
Why?
|
| Tetraethylammonium | 1 | 1988 | 24 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 137 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2010 | 276 | 0.020 |
Why?
|
| Electrophoresis | 1 | 1988 | 55 | 0.020 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2007 | 4 | 0.020 |
Why?
|
| Muscle Spindles | 1 | 2007 | 5 | 0.020 |
Why?
|
| Serologic Tests | 1 | 1988 | 44 | 0.020 |
Why?
|
| Aminopyridines | 1 | 1988 | 40 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2007 | 25 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 266 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1989 | 212 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1987 | 22 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 221 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 448 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1084 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2008 | 161 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2974 | 0.020 |
Why?
|
| Anterior Horn Cells | 1 | 2005 | 3 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2005 | 27 | 0.020 |
Why?
|
| Pons | 1 | 2005 | 25 | 0.020 |
Why?
|
| Diazepam | 1 | 2005 | 28 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2005 | 34 | 0.020 |
Why?
|
| Chromosomes, Mammalian | 1 | 2005 | 36 | 0.020 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2005 | 50 | 0.020 |
Why?
|
| Age of Onset | 1 | 2006 | 311 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 630 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 202 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 531 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 375 | 0.020 |
Why?
|
| Brain | 3 | 2003 | 2257 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 497 | 0.020 |
Why?
|
| Cell Movement | 1 | 2008 | 783 | 0.010 |
Why?
|
| Contactin 2 | 1 | 2003 | 2 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 167 | 0.010 |
Why?
|
| Shaker Superfamily of Potassium Channels | 1 | 2003 | 49 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 176 | 0.010 |
Why?
|
| Paraparesis | 1 | 2002 | 4 | 0.010 |
Why?
|
| Radiculopathy | 1 | 2002 | 15 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2002 | 67 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2001 | 171 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 2532 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 806 | 0.010 |
Why?
|
| Neoplasms | 1 | 1995 | 2998 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 2431 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1974 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1586 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 1213 | 0.010 |
Why?
|
| Life Tables | 1 | 1995 | 48 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 958 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 1995 | 119 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 430 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 157 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1995 | 902 | 0.010 |
Why?
|
| Logistic Models | 1 | 1995 | 1204 | 0.010 |
Why?
|
| Survival Rate | 1 | 1995 | 1881 | 0.010 |
Why?
|
| Action Potentials | 1 | 1994 | 590 | 0.010 |
Why?
|
| Sweat Glands | 1 | 1989 | 6 | 0.010 |
Why?
|
| Diglycerides | 1 | 1989 | 22 | 0.010 |
Why?
|
| Reflex | 1 | 1989 | 80 | 0.010 |
Why?
|